异甘草酸镁防治接受化疗的晚期胃癌患者肝肾功能损伤临床研究*

doi:10.3969/j.issn.1672-5069.2023.02.021

Abstract

Abstract: Objective The aim of this study was to observe the clinical efficacy of magnesium isoglycyrrhizinate in preventing and treating liver and kidney injuries in patients with advanced gastric cancer (AGC) undergoing chemotherapy. Methods A total of 105 patients with AGC were encountered in our hospital between April 2020 and April 2022, and all received taxotere, cisplatin and 5-fluorouracil combination chemotherapy. During the chemotherapy, the patients were randomly assigned to control (n=52) and observation group (n=53), receiving glutathione or magnesium isoglycyrrhizinate for preventing drug-induced liver injury (DILI) and kidney injury. Serum carbohydrate antigen 199 (CA199), CA125, CA724 and carcinoembryonic antigen (CEA) levels wereassayed by electrochemical luminescence, and serum interleukin-6 (IL-6), IL-8 and tumor necrosis factor-α(TNF-α) levels were detected by ELISA. Results At the end of chemotherapy, the incidence of DILI in the observation group was 3.8%, much lower than 15.4% (P<0.05) in the control, and no kidney injury occurred in the two groups; serum ALT, AST and ALP levels in the observation group were (44.3±10.5)U/L, (27.4±2.8)U/L and (70.6±14.5)U/L, all significantly lower than [(56.6±15.3)U/L,(49.1±2.9)U/L and (82.5±8.7)U/L, respectively, P<0.05] in the control; at the end of one month after chemotherapy, serum ALT and AST levels in the observation group were (33.5±5.8)U/L and (23.4±2.5)U/L, both significantly lower than [(42.6±7.7)U/L and (37.7±3.2)U/L, respectively,P<0.05] in the control; after treatment, serum CA199, CA125, CA724 and CEA levels in the two groups were not significantly different(P>0.05), while serum IL-6, IL-8 and TNF-α levels in the observation group were (3.9±0.5)ng/L,(57.3±5.8)ng/L and (3.4±0.4)ng/L, all significantly lower than [(5.7±0.6)ng/L, (84.2±8.5)ng/L and (6.7±0.8)ng/L, respectively, P<0.05] in the control group. Conclusion The application of magnesium isoglycyrrhizinate in preventing and treating patients with AGC undergoing chemotherapy is efficacious, which might be related to the inhibition of body inflammatory reactions.

Key words: Drug-induced liver injury, Gastric cancer, Magnesium isoglycyrrhizinate, Cisplatin, 5-fluorouracil, Therapy

Xu Jing, Liu Kun, Ma Zhufang. Clinical efficacy of magnesium isoglycyrrhizinate in preventing and treating liver and kidney injuries in patients with advanced gastric cancer undergoing chemotherapy[J]. Journal of Practical Hepatology, 2023, 26(2): 234-237.

References

[1] Siebenhüner AR, De Dosso S, Helbling D, et al. Advanced gastric cancer: Current treatment landscape and a future outlook for sequential and personalized guide: swiss expert statement article. Oncol Res Treat, 2021, 44(9): 485-494.
[2] Aznab M, Ahmadi SM, Khazaei S, et al. Relationship between the expression of the thymidylate synthase and the prognosis of gastric cancer patients treated with combinational chemotherapy regimen including fluorouracil, docetaxel and cisplatin. Int J Hematol Oncol Stem Cell Res, 2020, 14(3): 181-187.
[3] Garcia-Cortes M, Robles-Diaz M, Stephens C, et al. Drug induced liver injury: an update. Arch Toxicol, 2020, 94(10): 3381-3407.
[4] 陈业京, 陆清平, 顾少颖. 异甘草酸镁与复方甘草酸单胺治疗药物性肝损伤患者疗效比较研究. 实用肝脏病杂志, 2022, 25(3): 371-374.
[5] Yang Y, Huang L, Tian C, et al. Magnesium isoglycyrrhizinate alleviate airway inflammatory responses in ovalbumin-induced mouse model of allergic asthma. Immunopharmacol Immunotoxicol, 2022, 44(4): 525-533.
[6] Ajani JA, D'Amico TA, Bentrem DJ, et al. Gastric cancer, version 2. 2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw, 2022, 20(2): 167-192.
[7] Ikeda M, OkusakA T, UEno H, et al. A phase Ⅱ trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer, 2005, 103(4): 756-762.
[8] Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer. Lancet, 2020, 396(10251): 635-648.
[9] 高毓, 夏楠, 周福祥. PRODIGY: 多西他赛、奥沙利铂+S-1新辅助化疗联合手术及S-1辅助化疗对比手术及S-1辅助化疗治疗可切除局晚期胃癌的Ⅲ期研究. 中华医学杂志, 2022, 102(12): 857-857.
[10] Kawazoe A, Shitara K, Boku N, et al. Current status of immunotherapy for advanced gastric cancer. Jpn J Clin Oncol, 2021, 51(1): 20-27.
[11] Gao Y, Tian Y, Zhang X, et al. Magnesium isoglycyrrhizinate ameliorates concanavalin A-induced liver injuryvia the p38 and JNK MAPK pathway. Immunopharmacol Immunotoxicol, 2020, 42(5): 445-455.
[12] Jiang W, Xu S, Guo H, et al. Magnesium isoglycyrrhizinate prevents the nonalcoholic hepatic steatosis via regulating energy homeostasis. J Cell Mol Med, 2020, 24(13): 7201-7213.
[13] Li B, Chen L, Luo HL, et al. Docetaxel, cisplatin, and 5-fluorouracil compared with epirubicin, cisplatin, and 5-fluorouracil regimen for advanced gastric cancer: A systematic review and meta-analysis. World J Clin Cases, 2019, 7(5): 600-615.
[14] Ahmadzadeh A, Seyedian SS, Valizadeh A, et al. The efficacy and safety of modified docetaxel, cisplatin, and 5-fluorouracilvs. epirubicin, oxaliplatin, and capecitabine regimen in the advanced gastriccancer: a randomized controlled clinical trial. Asian Pac J Cancer Prev, 2020, 21(3): 727-732.
[15] 任发燕, 王超, 谭喜莹, 等. 异甘草酸镁预防胃癌化疗药物致肝损伤的药物经济学评价. 中国药房, 2020, 31(13): 1613-1617.
[16] 闫玉兰, 莫永森, 张冬梅. 异甘草酸镁对化疗药物致初治胃肠道肿瘤患者肝损害的预防作用. 中华肝脏病杂志, 2015, 23(3): 204-208.
[17] Chen X, Wang X, Yang L, et al. Magnesium isoglycyrrhizinate prevents cadmium-induced activation of JNK and apoptotic hepatocyte death by reversing ROS-inactivated PP2A. J Pharm Pharmacol, 2021, 73(12): 1663-1674.
[18] 王宁, 付立业, 隋承光, 等. 胃癌患者血清中IGF-1与CEA、CA125、CA199、CA724水平的相关性分析及在胃癌诊断中的意义. 中国实验诊断学, 2021, 25(2): 194-197.
[19] 邓爽, 闫凌丽. 异甘草酸镁联合XELOX方案对胃癌患者肝功能、炎性因子及血清肿瘤标志物的影响. 现代肿瘤医学, 2021, 29(9): 1551-1555.
[20] Xie C, Li X, Zhu J, et al. Magnesium isoglycyrrhizinate suppresses LPS-induced inflammation and oxidative stress through inhibiting NF-κB and MAPK pathways in RAW264. 7 cells. Bioorg Med Chem, 2019, 27(3): 516-524.
[21] Yang Y, Huang L, Tian C, et al. Magnesium isoglycyrrhizinate inhibits airway inflammation in rats with chronic obstructive pulmonary disease. BMC Pulm Med, 2021, 21(1): 371-371.
[22] Lu L, Hao K, Hong Y, et al. Magnesium isoglycyrrhizinate reduces hepatic lipotoxicitythrough regulating metabolic abnormalities. Int J Mol Sci, 2021, 22(11): 5884-5884.

Clinical efficacy of magnesium isoglycyrrhizinate in preventing and treating liver and kidney injuries in patients with advanced gastric cancer undergoing chemotherapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yin Wen, Lu Kexiang, Wang Xue, et al.. Short-term efficacy of oxymatrine and entecavir combination in the treatment of patients with serum HBeAg-positive chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(2): 173-176.
[2]	Wei Li, Liu Bo, Zhao Nan, et al.. Would the coincidence of nonalcoholic fatty liver diseases impact the antiviral response to enticavir therapy in patients with chronic hepatitis B? [J]. Journal of Practical Hepatology, 2023, 26(2): 181-184.
[3]	Zhang Longyu, Mou Danlei, Li Tongzeng, et al.. Clinical efficacy of granulocyte colony stimulating factor in the treatment of patients with severe alcoholic hepatitis:a Meta-analysis [J]. Journal of Practical Hepatology, 2023, 26(2): 210-213.
[4]	Ling Jiahui, Ni Meixin, Han Lili, et al.. Serum cytokine changes in patients with autoimmune hepatitis receiving magnesium isoglycyrrhizinate treatment [J]. Journal of Practical Hepatology, 2023, 26(2): 214-217.
[5]	Wang Yan, Zhou Jing, Han Jun. Clinicopathological features of patients with autoimmune hepatitis and drug-induced liver injury [J]. Journal of Practical Hepatology, 2023, 26(2): 218-221.
[6]	Li Yanfen, Zhang Xiaowen, Wang Yanru, et al.. Rescuing therapy of obeticholic acid and fibrates in patients with primary biliary cholangitis without complete response to ursodeoxycholic acid treatment [J]. Journal of Practical Hepatology, 2023, 26(2): 226-229.
[7]	Cheng Yang, Zhang Feng, Wang Xixuan, et al.. Comparison of clinical efficacy of carvedilol and propranolol in preventing esophagogastric varices bleeding in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2023, 26(2): 254-257.
[8]	Zhang Bin, Zhao Yuliang, Yan Guobei. Efficacy of hUCB-MNC and hUC-MSC transfusion in patients with decompensated hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2023, 26(2): 262-265.
[9]	Zhou Qiujuan, Zhu Yiming, Ma Yuhang, et al.. Improvement of hypersplenism in patients hepatitis B cirrhosis after TIPS and PSE combination treatment [J]. Journal of Practical Hepatology, 2023, 26(2): 266-269.
[10]	Gu Kai, Wu Xiaochen, Zhu Yiming. Single high dose of hepatic irradiation in ameliorating hepatic pain in patients with primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(2): 270-273.
[11]	Gong Cheng, Tian Yinsheng, Liu Shuang. Comparison of two-year survivals in primary liver cancer patients with spontaneous tumor rupture underwent hepatectomy at early or late operation time windows [J]. Journal of Practical Hepatology, 2023, 26(2): 274-277.
[12]	Shi Hao, Chen Yong, Luo Bin, et al.. Preoperative doxorubicin magnetic fluid targeted chemotherapy before microwave ablation in the treatment of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(2): 278-281.
[13]	Yin Qiushi, Wang Xueguo, Song Qifeng. Comparison of complete laparoscopic left hemihepatectomy and traditional open laparotomy with left hepatic pedicle occlusion in treatment of patients with intrahepatic and extrahepatic bile duct stones [J]. Journal of Practical Hepatology, 2023, 26(2): 282-285.
[14]	Huang Shulun, He Shengduo, Xu Xiaoyuan, et al.. Efficacy of partial enteral nutrition and octreotide treatment for liver cirrhotic patient with chylous ascites:a case report [J]. Journal of Practical Hepatology, 2023, 26(2): 290-292.
[15]	Shen Yan, Chen Lin. Endoscopic treatment and long-term management of patients with esophagogastric variceal bleeding [J]. Journal of Practical Hepatology, 2023, 26(1): 8-10.